In the face of mounting tariff threats from the Trump administration, the biotech industry has sounded a fervent alarm. The sector warns that advancements in rare disease, cell, and gene therapies—areas where innovation is sorely needed—are under serious threat. The issue at stake is not just about dollars and cents, but the broader public health implications of stifling innovation in an area where existing treatments are in short supply.
Of the more than 10,000 known rare diseases, a staggering 95% lack an FDA-approved therapy. Faced with this stark reality, the industry argues that preserving incentives to innovate is an urgent public health necessity. BioMarin, a key player in this field, has been at the forefront of this call to action. The company, known for pioneering gene therapies such as Roctavian for hemophilia A, underscores the need to sustain and encourage innovation in this sector, despite the financial strains it may impose.
The emerging tension between innovation and profitability is emblematic of the delicate balance the industry must strike. BioMarin, despite its groundbreaking work, has struggled to break even. The financial challenges the company faces highlight the precarious position of the wider industry, as it juggles the drive to innovate with the need to maintain financial stability.
These concerns have been echoed across the industry. Over the past few weeks, comments have been flooding into the Federal Register regarding the government’s Section 232 investigation, which is exploring the possibility of levying tariffs against pharma companies on national security grounds.
One vocal opponent has been the Alliance for Regenerative Medicine (ARM). The group warns that tariffs could undermine and slow access to cell and gene therapies for U.S. patients. They argue that if tariffs are inevitable, they should be phased in to provide companies time to reshore production. They also suggest that small volume imports should be exempted.
Regenerative medicines, ARM explains, are often produced for a minuscule number of patients annually and demand can fluctuate drastically. However, when these therapies are needed, the situation is typically critical. Companies must therefore have the certainty of accessing the necessary ingredients, many of which are sourced from outside the U.S.
The current geopolitical climate, marked by tariff threats and reshoring pressures, presents a unique challenge for the biotech industry. It is a test of the industry’s resilience and adaptability, but more importantly, it is a stark reminder of the critical importance of sustaining innovation in the face of economic and political pressures. The stakes are high, not just for the industry, but for the countless patients awaiting life-changing therapies.
Read more from biospace.com
